ClinicalTrials.gg
Status unknownNCT03520465Updated Aug 13, 2019

Utility of a Supraaponeurotic Mesh as Prophylaxis of the Midline Eventration After an Oncological Colorrectal Resection

An interventional study of DynaMesh®-CICAT longitudinal measure 10x35 cm in Eventration, sponsored by Instituto de Investigacion Sanitaria La Fe. Status unknown at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-13.

Sponsored by Instituto de Investigacion Sanitaria La Fe · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Aug 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Jun 2016, registered Apr 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Randomized prospective experimental study, in which the effect of a prophylactic mesh is assessed in the eventration rate diagnosed by CT at one year after surgery in patients with CRC who underwent elective intervention for supra-infraumbilical midline laparotomy, considering as treatment the supra-aponeurotic mesh positioning (experimental group), and comparing it to the standard closing with a continuous suture using slow absorption monofilament.

Read the detailed description

Randomized prospective experimental study, in which we evaluate patients with CRC who underwent elective intervention for supra-infraumbilical midline laparotomy in order to:

Main objective:

  • To assess the effect of the prophylactic mesh in the eventration rate diagnosed by CT at one year after surgery in patients with CRC who underwent elective intervention for supra-infraumbilical midline laparotomy.

Secondary objectives:

  • To compare the appearance of complications in the control group and in the experimental group.
  • Compare costs derived from short and long-term mesh placement in both groups.

We consider as treatment the supra-aponeurotic mesh positioning (experimental group), and compare it to the standard closing with slow absorption monofilament.

02

Conditions studied

  • Eventration

Browse trials for

03

In context

Gastroschisis

42 studies on the registry are indexed under Gastroschisis; 6 are open to participants now.

This study's planned enrollment of 154 is above the median of 44 across 26 interventional studies indexed under Gastroschisis.

Browse Gastroschisis studies →

Lead sponsor

Instituto de Investigacion Sanitaria La Fe is the lead sponsor of 59 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Elective surgery for colorectal cancer.
  • Surgery by middle laparotomy.
  • signed by the patient.
  • Age > 18 years.

Exclusion criteria

Exclusion Criteria:

  • Midline hernia or eventration.
  • Presence of mesh in the abdominal wall because of a previous surgery.
  • Palliative surgery.
  • Synchronous (Stage IV cancer according to TNM).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    Supraaponeurotic mesh

    Patients with laparotomy closure by conventional approach of aponeurosis (continuous suture with monofilament of slow absorption), and posterior placement of supraaponeurotic mesh of polyvinylidene fluoride (PVDF) medium / low density and wide pore. The mesh has a longitudinal measurement that exceeds about 3 cm the upper and lower ends of the wound and width should not be less than 10 cm, therefore the mesh selected is DynaMesh®-CICAT longitudinal measure 10x35 cm. The mesh is fixed to the aponeurosis with a crown of loose stitches and points to the midline. A prolene 2/0 non-reabsorbable monofilament suture of cylindrical needle is used. A 10 Fr suction drainage is placed in the supraaponeurotic plane, with an exit to the exterior beyond the edges of the prosthesis. Drainage will be preserved for a minimum of 48 hours after surgery, and will be withdrawn when a debit of less than 50 ml is presented in 24 h.

    Device: DynaMesh®-CICAT longitudinal measure 10x35 cm

  • No intervention
    Monofilament

    Patients with conventional closure of the middle laparotomy with approach of aponeurosis in a plane by continuous suture with monofilament of slow absorption. In this study, the suture used in all patients will be poly-4-hydroxybutyrate or Mono-max loop®.

Interventions

  • DeviceDynaMesh®-CICAT longitudinal measure 10x35 cm
06

What researchers measure

Primary outcomes

  1. Eventration rate

    To assess the effect of the prophylactic mesh in the eventration rate diagnosed by CT at one year after surgery in patients with CRC who underwent elective intervention for supra-infraumbilical midline laparotomy.

    Time frame: 1 year

Secondary outcomes

  1. Complications rate

    To compare the appearance of complications in the control group and in the experimental group.

    Time frame: 1 year

  2. Short and long term derived costs

    To compare the costs derived from short and long-term mesh placement in both groups.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitario y Politécnico La Fe
    Valencia, Spain
    Recruiting
    • Laura Segura · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2016 (actual). Primary completion is estimated for Jun 2020, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2018
First posted
May 9, 2018
StartActual
Jun 27, 2016
Primary completionEst.
Jun 2020
CompletionEst.
Jun 2020
Last update
Aug 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03520465
Lead sponsor
Instituto de Investigacion Sanitaria La Fe
Responsible party
Sponsor
First posted
May 9, 2018
Start date
Jun 27, 2016
Primary completion
Jun 2020 (estimated)
Completion
Jun 2020 (estimated)
Last update
Aug 13, 2019

Study contacts

Laura Segura
Contact
investigacion_clinica@iislafe.es
0034961246711
Matteo Frasson
principal investigator · Instituto de Investigación Sanitaria La Fe
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion